Metalyse 8000 U & 10 000 U 40 mg/ 50 mg Powder for solution for injection
PDF Leaflet Revision Date: 3 September 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Thrombolytic treatment of acute myocardial infarction.
Dosage (summary)
Administer based on body weight, max 10,000 units (50 mg).
Special Populations
- Elderly > 80 years
- Children < 18 years
Pregnancy & Breastfeeding
Limited data; caution advised during lactation.
Key Drug Interactions
- Anticoagulants may increase bleeding risk
- Incompatible with dextrose solution
Contraindications
- Hypersensitivity to tenecteplase
- Severe bleeding disorders
- Hepatic dysfunction
- Recent major surgery
Common side effects
- Haemorrhage
- Gingival bleeding
- Injection site bleeding
Counselling Points
- Report any signs of bleeding
- Avoid unnecessary invasive procedures during treatment
Serious warnings
- Risk of serious bleeding
- Requires experienced physician supervision
Important Disclaimer
The Metalyse 8000 U & 10 000 U 40 mg/ 50 mg Powder for solution for injection professional information leaflet below is the property of Ingelheim Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
